[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FR2866569B1 - USE OF THE METRONIDAZOLE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR TREATING PATHOLOGIES ASSOCIATED WITH THE INTERLEUKINE 8 TYPE B RECEPTOR AND / OR THE PACAP TYPE 1 RECEPTOR - Google Patents

USE OF THE METRONIDAZOLE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR TREATING PATHOLOGIES ASSOCIATED WITH THE INTERLEUKINE 8 TYPE B RECEPTOR AND / OR THE PACAP TYPE 1 RECEPTOR

Info

Publication number
FR2866569B1
FR2866569B1 FR0401721A FR0401721A FR2866569B1 FR 2866569 B1 FR2866569 B1 FR 2866569B1 FR 0401721 A FR0401721 A FR 0401721A FR 0401721 A FR0401721 A FR 0401721A FR 2866569 B1 FR2866569 B1 FR 2866569B1
Authority
FR
France
Prior art keywords
receptor
type
interleukine
metronidazole
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0401721A
Other languages
French (fr)
Other versions
FR2866569A1 (en
Inventor
Fabrizio Folfi
Irina Safonova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0401721A priority Critical patent/FR2866569B1/en
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to US10/590,031 priority patent/US20080221189A1/en
Priority to AU2005224123A priority patent/AU2005224123A1/en
Priority to BRPI0506550-0A priority patent/BRPI0506550A/en
Priority to CNA2005800055751A priority patent/CN1921852A/en
Priority to PCT/FR2005/000370 priority patent/WO2005089750A2/en
Priority to EP05729371A priority patent/EP1718296A2/en
Priority to JP2006553618A priority patent/JP2007523133A/en
Priority to CA002553932A priority patent/CA2553932A1/en
Priority to RU2006133534/15A priority patent/RU2006133534A/en
Priority to KR1020067016588A priority patent/KR20060124707A/en
Publication of FR2866569A1 publication Critical patent/FR2866569A1/en
Application granted granted Critical
Publication of FR2866569B1 publication Critical patent/FR2866569B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0401721A 2004-02-20 2004-02-20 USE OF THE METRONIDAZOLE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR TREATING PATHOLOGIES ASSOCIATED WITH THE INTERLEUKINE 8 TYPE B RECEPTOR AND / OR THE PACAP TYPE 1 RECEPTOR Expired - Fee Related FR2866569B1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR0401721A FR2866569B1 (en) 2004-02-20 2004-02-20 USE OF THE METRONIDAZOLE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR TREATING PATHOLOGIES ASSOCIATED WITH THE INTERLEUKINE 8 TYPE B RECEPTOR AND / OR THE PACAP TYPE 1 RECEPTOR
CA002553932A CA2553932A1 (en) 2004-02-20 2005-02-17 Use of metronidazole for preparing a pharmaceutical composition for treating pathologies related to the b-type receptor of interleukin 8 and/or to a pacap type 1 receptor
BRPI0506550-0A BRPI0506550A (en) 2004-02-20 2005-02-17 use of metronidazole for the preparation of a pharmaceutical composition
CNA2005800055751A CN1921852A (en) 2004-02-20 2005-02-17 Use of metronidazole for preparing a pharmaceutical composition for treating pathologies related to the b-type receptor of interleukin 8 and/or to a pacap type 1 receptor
PCT/FR2005/000370 WO2005089750A2 (en) 2004-02-20 2005-02-17 Use of metronidazole for preparing a pharmaceutical composition for treating pathologies related to the b-type receptor of interleukin 8 and/or to a pacap type 1 receptor
EP05729371A EP1718296A2 (en) 2004-02-20 2005-02-17 Use of metronidazole for preparing a pharmaceutical composition for treating pathologies related to the b-type receptor of interleukin 8 and/or to a pacap type 1 receptor
US10/590,031 US20080221189A1 (en) 2004-02-20 2005-02-17 Use of Metronidazole For Preparing a Pharmaceutical Composition For Treating Pathologies Related to the B-Type Receptor of Interleukin 8 and/or to a Pacap Type 1 Receptor
AU2005224123A AU2005224123A1 (en) 2004-02-20 2005-02-17 Use of metronidazole for preparing a pharmaceutical composition for treating pathologies related to the B-type receptor of interleukin 8 and/or to a pacap type 1 receptor
RU2006133534/15A RU2006133534A (en) 2004-02-20 2005-02-17 APPLICATION OF METRONIDAZOLE FOR THE PRODUCTION OF THE PHARMACEUTICAL COMPOSITION INTENDED FOR THE TREATMENT OF PATHOLOGIES RELATED TO INTERLEUKIN 8 TYPE RECEPTORS IN AND / OR THE RASAR RECIPE TYPE 1
KR1020067016588A KR20060124707A (en) 2004-02-20 2005-02-17 Use of metronidazole for preparing a pharmaceutical composition for treating pathologies related to the b-type receptor of interleukin 8 and/or to a pacap type 1 receptor
JP2006553618A JP2007523133A (en) 2004-02-20 2005-02-17 Use of metronidazole for the preparation of a pharmaceutical composition for treating lesions associated with interleukin 8 type B receptor and / or PACAP type 1 receptor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0401721A FR2866569B1 (en) 2004-02-20 2004-02-20 USE OF THE METRONIDAZOLE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR TREATING PATHOLOGIES ASSOCIATED WITH THE INTERLEUKINE 8 TYPE B RECEPTOR AND / OR THE PACAP TYPE 1 RECEPTOR

Publications (2)

Publication Number Publication Date
FR2866569A1 FR2866569A1 (en) 2005-08-26
FR2866569B1 true FR2866569B1 (en) 2007-08-24

Family

ID=34833946

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0401721A Expired - Fee Related FR2866569B1 (en) 2004-02-20 2004-02-20 USE OF THE METRONIDAZOLE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR TREATING PATHOLOGIES ASSOCIATED WITH THE INTERLEUKINE 8 TYPE B RECEPTOR AND / OR THE PACAP TYPE 1 RECEPTOR

Country Status (11)

Country Link
US (1) US20080221189A1 (en)
EP (1) EP1718296A2 (en)
JP (1) JP2007523133A (en)
KR (1) KR20060124707A (en)
CN (1) CN1921852A (en)
AU (1) AU2005224123A1 (en)
BR (1) BRPI0506550A (en)
CA (1) CA2553932A1 (en)
FR (1) FR2866569B1 (en)
RU (1) RU2006133534A (en)
WO (1) WO2005089750A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2961695B1 (en) * 2010-06-29 2012-07-06 Galderma Res & Dev USE OF COMPOUNDS IN THE TREATMENT OR PREVENTION OF SKIN DISORDERS
US20130102572A1 (en) * 2011-04-12 2013-04-25 Dow Pharmaceutical Sciences Methods of treating skin conditions exhibiting telangiectasia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837378A (en) * 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
FR2722098B1 (en) * 1994-07-06 1996-08-23 Cird Galderma NEW MEDICINES BASED ON METRO-NIDAZOLE OR A SYNERGETIC MIXTURE OF METRONIDAZOLE AND CLINDAMYCIN
CA2161737C (en) * 1995-10-30 1998-10-20 Richard J. Mackay Metronidazole gel
GB9626513D0 (en) * 1996-12-20 1997-02-05 Bioglan Ireland R & D Ltd A pharmaceutical composition
US6365616B1 (en) * 1998-08-31 2002-04-02 Sentron Medical, Inc. Methimazole derivatives and tautomeric cyclic thiones to treat autoimmune diseases
KR100671879B1 (en) * 1999-07-16 2007-01-19 가부시키가이샤 쇼에이 Nitroimidazole external preparations for dermatosis
US7078048B2 (en) * 2001-05-09 2006-07-18 The Regents Of The University Of Michigan Method and compositions for treating rosacea
DE602004004399T2 (en) * 2003-06-18 2007-06-21 Galderma S.A., Cham GREEN-COLORED TOPICAL PHARMACEUTICAL COMPOSITION BASED ON METRONIDAZOLE

Also Published As

Publication number Publication date
KR20060124707A (en) 2006-12-05
CN1921852A (en) 2007-02-28
RU2006133534A (en) 2008-03-27
WO2005089750A2 (en) 2005-09-29
AU2005224123A1 (en) 2005-09-29
CA2553932A1 (en) 2005-09-29
JP2007523133A (en) 2007-08-16
US20080221189A1 (en) 2008-09-11
FR2866569A1 (en) 2005-08-26
WO2005089750A3 (en) 2006-05-04
BRPI0506550A (en) 2007-02-27
EP1718296A2 (en) 2006-11-08

Similar Documents

Publication Publication Date Title
FR2867778B1 (en) USE OF INDAZOLECARBOXAMIDE DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT AND PREVENTION OF MALARIA
FR2799124B1 (en) USE OF ANTAGONISTS OF CENTRAL CANNABINOID RECEPTORS FOR THE PREPARATION OF DRUGS
MA28722B1 (en) ORODISPERSIBLE PHARMACEUTICAL COMPOSITION FOR OROMUCOSAL OR SUBLINGUAL ADMINISTRATION OF AGOMELATIN.
FR2851470B1 (en) PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL OR TRANSMUCTIVE DELIVERY
FR2758723B1 (en) USE OF CENTRAL CANNABINOID RECEPTOR ANTAGONISTS FOR THE PREPARATION OF DRUGS
FR2921795B1 (en) USE OF A BIFIDOBACTERIUM STRAIN FOR THE PREPARATION OF A COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF ALLERGIC-LIKE MANIFESTATIONS
MA28844B1 (en) PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND ETHYNYLTRADIOL
FR2902010B1 (en) USE OF 1.7 DIMETHYLXANTHINE FOR THE MANUFACTURE OF A NON-ANXIOGENIC PSYCHOANALEPTIC MEDICAMENT FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDER
FR2902325B1 (en) USE OF 3H-1,2-DITHIOLE-3-THIONE, ANETHOLE DITHIOMLETHIONE, SULFORAPHE, PHENETHYL ISOTHIOCYANATE, 6-METHYL-SULPHINYL) HEXYL ISOTHIOCYANATE AND ALLYL ISOTHIOCYANATE FOR THE TREATMENT OF CANITIA
FR2871693B1 (en) USE OF A PHARMACEUTICAL COMPOSITION COMPRISING CALCITRIOL AND CLOBETASOL PROPIONATE FOR THE TREATMENT OF PSORIASIS
FR2765107B1 (en) USE OF A SPECIFIC 5HT2 RECEPTOR ANTAGONIST FOR THE PREPARATION OF MEDICINES USEFUL IN THE TREATMENT OF SLEEP APNEA SYNDROME
FR2792835B3 (en) USE OF SAREDUTANT FOR THE PREPARATION OF MEDICINES USEFUL IN THE TREATMENT OR PREVENTION OF ALL MOOD DISORDERS, ADAPTATION DISORDERS OR MIXED ANXIETY-DEPRESSION DISORDERS
FR2890304B1 (en) DEVICE FOR MEASURING THE RESISTANCE TO DEFORMATION OF A CORNEA.
FR2866569B1 (en) USE OF THE METRONIDAZOLE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR TREATING PATHOLOGIES ASSOCIATED WITH THE INTERLEUKINE 8 TYPE B RECEPTOR AND / OR THE PACAP TYPE 1 RECEPTOR
FR2872798B1 (en) BLISTER ASSEMBLY FOR INHALATION DEVICE
FR2906472B1 (en) HYPERTONIC IONIC SOLUTIONS BASED ON UNDILUATED SEA WATER, THEIR USE AS MEDICAMENTS AND FOR THE PREPARATION OF MEDICAMENTS FOR THE TREATMENT OF NASAL CONGESTION.
FR2872707B1 (en) CIRCULATORY ASSISTANCE DEVICE FOR THE HEART
FR2886151B1 (en) USE OF COLCHICINE FOR THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION AND / OR TREATMENT OF ENDOMETRIOSIS
FR2866568B1 (en) USE OF THE METRONIDAZOLE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR TREATING A DISORDER OF SKIN VASCULARIZATION
FR2862537B1 (en) USE OF FEPRADINOL FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ROSACEA
FR2883180B1 (en) USE OF ACETYL LEUCINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF BALANCE DISORDERS
FR2878160B1 (en) USE OF MAGNESIUM N-ACETYL TAURINATE FOR THE PREPARATION OF INHIBITORY DRUGS FOR PHOTIC HYPERSENSIBLITY
FR2902329B1 (en) USE OF SULFORAPHANE, PHENETHYL ISOTHIOCYANATE, 6-METHYL-SULPHINYL) HEXYL ISOTHIOCYANATE AND ALLYL ISOTHIOCYANATE FOR THE TREATMENT OF CANITIA.
FR2877926B1 (en) PRESSURIZED DEVICE FOR HAIRSTAPING CAPILLARY FIBERS AND USE OF SUCH A DEVICE FOR THE SHAPING AND / OR CARE OF CAPILLARY FIBERS.
FR2913318B1 (en) TOGETHER FOR THE TREATMENT OF KERATINIC MATERIALS AND / OR THE APPLICATION OF A PRODUCT ON THESE KERATINIC MATERIALS

Legal Events

Date Code Title Description
CA Change of address
ST Notification of lapse

Effective date: 20081031